XALKORI, ZYKADIA and ALECENSA are indicated for the treatment of patients with metastatic NSCLC whose tumours are ALK positive as detected by an FDA-approved testing method for ALK.1,3
XALKORI (crizotinib) is indicated for the treatment of patients with ALK-positive metastatic NSCLC and other kinases.1
ZYKADIA (ceritinib) is indicated for the treatment of patients with ALK-positive metastatic NSCLC who have had no previous treatment, or who have progressed on, or who are intolerant to, crizotinib.3
ALECENSA (alectinib) is indicated for the treatment of patients with ALK-positive metastatic NSCLC who have had no previous treatment, or who have progressed on, or who are intolerant to, crizotinib.4